For Patients
                  The UK National HALO Patient Registry  
                   
                  WHAT HAPPENS IN THE STUDY? 
                    
                  What will happen to me if I take   part? 
                  i) Initial Visit 
                    You will be interviewed by your   study doctor or the study coordinator to see if you are eligible and willing to   take part in the study. We generally only treat patients who we think are at   moderate or high risk of developing cancer.  Some patients may require an   additional endoscopy prior to having the treatment to confirm the diagnosis or   extent of Barrett’s oesophagus and to check if there are changes in the cells to   suggest that this patient is at moderate or high risk of developing cancer.   
                    
                  ii)The   treatment 
                    HALO ablation is a day case procedure in endoscopy. Before your   treatment, you should be taking your usual medication for blocking the   production of stomach acid, such as omeprazole.  While you lie on your left side   on a table, you will have a sedative injected into a vein in your arm or hand to   make you sleepy.  A small flexible tube with a light and camera at the end (the   endoscope) will then be passed through your mouth and into your gullet. You will   then have HALO ablation treatment. Treatment time is usually around 30-45   minutes. You should remember very little about the treatment as you will be   sleepy throughout. 
                    
                  iii) Follow-up visits 
                    You will have an endoscopy   with repeat HALO ablation of Barrett’s oesophagus every three months for up to 1   year, until there is no visual evidence of Barrett’s oesophagus remaining.  Once   there is no visual evidence of Barrett’s oesophagus, you will have an endoscopy   with a biopsy to confirm that the Barrett’s oesophagus is no longer present on a   microscopic level.  If these biopsies are normal, you will continue “standard of   care” endoscopy with biopsy for surveillance every 2-3 years to continue to   watch for new Barrett’s oesophagus to form.  Should any new Barrett’s oesophagus   develop, you may receive additional ablation procedures.   
                    
                  What are the side effects of any treatment   received when taking part? 
                  There is a low risk of a narrowing of the gullet   caused by the procedure (<1%). If this were to occur you may require   stretching of this narrowing, which is the standard treatment. Some patients may   experience chest discomfort and a feeling of sickness after the procedure which   can last up to 2 weeks, but usually resolves after 2-4 days. More serious   complications are very rare. 
                    
                  What if relevant new information   becomes available?  
                    
                  Sometimes during the course of a research project,   new information becomes available about the treatment that is being studied. If   this happens, we will tell you about it and discuss with you whether you want to   continue in the study. If you decide to withdraw, we will make arrangements for   your care to continue. If you decide to continue in the study, you will be asked   to sign an updated consent form. Also, on   receiving any information, we might consider it to be in your best interest to   withdraw from the study. We will explain the reasons and arrange for your care   to continue.Any information which is   collected about you during the course of the research will be kept strictly   confidential, although we will inform your GP and any other doctors who are   treating you that you are taking part in this trial. 
                    
                  What will happen to the results of   the research study?  
                  We aim to publish the results of this trial in a   medical journal within 3 years of completing it. If you would like to know about   publications based on this work, please telephone Sally Thorpe at the number at   the bottom of this information sheet. 
                    
                  Who has reviewed the   study? 
                  All research in the NHS is looked at by an   independent group of people, called a Research Ethics Committee to protect your   safety, rights, wellbeing and dignity. This study has been reviewed by UCLH A   Research Ethics Committee (NRES Number 08/H0714/27). 
                    
                   
                      Who is organising the   research?   
                  This research study is being organised by Dr   Laurence Lovat, Consultant Gastroenterologist & Senior Lecturer in Laser   Medicine (the chief investigator) at the National Medical Laser Centre at   University College Hospital in London.   
                    
                  How do I take part in the   Study?  
                  There are quite a few hospitals around the UK   participating in this study. You will need to get a   formal referral from your GP or the consultant who is looking after your   Barrett’s oesophagus to one of these centres. You may take this information to   your doctor and ask them to make a referral for assessment.  
                    
                    
                  For information on the doctors currently taking   part in the UK National HALO registry, please  CLICK   HERE 
                  
                    
                   
 	
      
        | 
           
             Barrett's Disease
         | 
        
           
             Barrett's Oesophagus
         | 
        
           
             Barrett's Esophagus
         | 
        
           
             Barrett's 0esophagus
         | 
        
           
             Barrett's Esophagitis
         | 
       
      
        | 
           
             Barratts Disease
         | 
        
           
             Barratts Oesophagus
         | 
        
           
             Barretts Esophagus
         | 
        
           
             Barretts 0esophagus
         | 
        
           
             Oesophageal Cancer
         | 
       
      |